Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting

Clinical Infectious Diseases

Volumn 51, Issue 5, 2010, Pages 600-608

  Koenig, Serena P ^a   Schackman, Bruce R ^b   Riviere, Cynthia ^c   Leger, Paul ^c   Charles, Macarthur ^b   Severe, Patrice ^c   Lastimoso, Charlene ^a   Colucci, Nicole ^a   Pape, Jean W ^b,c   Fitzgerald, Daniel W ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Department of Adolescent Medicine   (Haïti)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ABNORMAL LABORATORY RESULT; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD GLUCOSE MONITORING; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; FEMALE; HAITI; HEALTH CARE COST; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; THROMBOCYTOPENIA;

ANTI-HIV AGENTS; BLOOD GLUCOSE; CLINICAL LABORATORY TECHNIQUES; COHORT STUDIES; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HAITI; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; HYPERGLYCEMIA; SOCIOECONOMIC FACTORS; ZIDOVUDINE;

EID: 77955779574     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655762     Document Type: Article

References (38)

1. de Maat MM, ter Heine R, van Gorp EC, et al. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine- containing antiretroviral treatment. AIDS 2003; 17:2209-14.
2. Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT cohort, Thailand, 1996-2001. AIDS 2003; 17:2191-9.
3. Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32:259-67.
4. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
5. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-9.
6. Ssali F, Stohr W, Munderi P, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006; 11:741-9.
7. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322:941-9.
8. Moh R, Danel C, Sorho S, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 2005; 10:615-24.
9. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in western India. J Acquir Immune Defic Syndr 2005; 39:199-202.
10. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-84.
11. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007; 45:1093-101.
12. Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncombe C. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother 2006; 58:637-44.
13. United Nations Development Programme. Human development report 2009. http://hdrstats.undp.org/en/countries/data-sheets/cty-ds-HTI .html. Accessed 1 March 2010.
14. UNAIDS. Report on the global AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organization, 2008. http://www.unaids. org/en/KnowledgeCentre/HIVData/ Epidemiology/latestEpiData.asp. Accessed 1 March 2010.
15. Monitoring, Evaluation, and Surveillance Interface (MESI). Haitian Ministry of Health, Centers for Disease Control, United States Agency for International Development, and Institut Haitien de l'Enfance, 2010. http://www.mesi.ht. Accessed 1 March 2010.
16. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: recommendations for a public health approach- 2006 revision. Geneva: World Health Organization, 2006. http://www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf. Accessed 1 March 2010.
17. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005; 353:2325-34.
18. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3months of antiretroviral therapy. Clin Infect Dis 2009; 48:829-31.
19. American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990; 142:725-35.
20. Koenig SP, Riviere C, Leger P, et al. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc 2008; 6:3.
21. Drummond MF. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005.
22. Tan-Torres E, Baltussen R, Adam T, et al, eds. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.
23. Murray CJL, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press, 1996.
24. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991; 99:465-71.
25. Tost JR, Vidal R, Cayla J, Diaz-Cabanela D, Jimenez A, Broquetas JM. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 2005; 9:534-40.
26. GlaxoSmithKline. Epivir prescribing information. Research Triangle Park, NC: 2006. http://us.gsk.com/products/assets/us-epivir.pdf. Accessed 1 March 2010.
27. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998; 280:1757-63.
28. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16:1179-87.
29. Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007; 14:535-56.
30. Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007; 21(Suppl 4):S117-28.
31. Hakim J. What have we learnt from the DART Trial? [presentation TUSS105]. In: Program and abstracts of the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (Cape Town, South Africa). 2009. http://www.ias2009.org/pag/PSession .aspx?sp2490. Accessed 1 March 2010.
32. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375:123-31.
33. Gilks CF. Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring anti-retroviral therapy in Uganda and Zimbabwe (DART Trial) [presentation TUSS104]. In: Program and abstracts of the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (Cape Town, South Africa). 2009. http://www.ias2009.org/pag/PSession. aspx?sp2490. Accessed 1March 2010.
34. Hutubessy RCW, Baltussen RMPM, Torres-Edejer TT, Evans DB, WHO-CHOICE Working Group. WHO-CHOICE: choosing interventions that are cost-effective. In: Murray CJL, Evans DB, eds. Health systems performance assessment: debates, methods and empiricism. Geneva: WHO Editions, 2003.
35. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003; 4:115-20.
36. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of firstline antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004; 363:1253-63.
37. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
38. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource- limited settings: a southern African analysis. Arch Intern Med 2008; 168:1910-8.